BioSpace News Archive

Highlights: RECCE ® 327 and RECCE ® 529 demonstrated dose-dependent activity in-vivo against SARS-CoV-2 virus in Syrian golden hamsters, a well-accepted model of infection Intranasal administration of both compounds supports multiple potential modes of administration against SARS-CoV-2 Company committed to its COVID-19 activities as part of its infectious disease portfolio

Briotech, Inc. announces manufacturing expansion to meet demand for its BrioHOCl® and BrioWHISH™ (patent pending) Networked Production Systems

Further strengthening its fight against COVID-19, Serum Institute of India (SIIPL), the world’s largest vaccine manufacturer by volume, has partnered with Dynavax Technologies Corporation (Nasdaq: DVAX) a biopharmaceutical company focused on developing and commercializing novel vaccines, and today joint

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it has executed a securities purchase agreement to raise gross proceeds of $110 million resulting from the sale of shares of its common stock and/or pre-funded warrants through a private investment in public equity (PIPE) financing at a price per share o

China Jo-Jo Drugstores, Inc. announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market that it has regained compliance with Nasdaq Listing Rule 5550, which concerns minimum bid price listing requirements.

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound, has recently been issued Chinese Patent ZL 2018 8 00500526

All planned clinical trials for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) wet AMD BLA now fully enrolled or completed Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration trial for ONS-5010 (NORSE TWO) with new BLA filing expected in second half of 2021

Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (NASDAQ:SMTI), a provider of wound and skin care products dedicated to improving patient outcomes, announced today that Sara Ortwein has been appointed to the Companys Board of Directors effective December 18, 2020.

Shares of Yumanity to commence trading on Nasdaq under new ticker symbol “YMTX” on December 23, 2020 $33.6 million common stock private investment in public equity (“PIPE”) transaction closes concurrently with the merger

Chengdu Kanghong Pharmaceutical Group (“Kanghong”) announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, double-masked, parallel-group, dose-ranging, active-controlled, randomized trial (nicknamed “PANDA”) t